Signal transduction and oncogenesis by ErbB/HER receptors.

Growth factors enable cells to escape irradiation-induced death (apoptosis). One important family of growth factors share an epidermal growth factor motif, and all bind to ErbB transmembrane receptors. In response to growth factor ligands, ErbB receptor tyrosine kinases induce a variety of cellular responses, including proliferation, differentiation and motility. Signal transduction pathways are initiated upon ligand-induced receptor homo- or heterodimerization and activation of tyrosine kinase activity. The complement of induced signaling pathways, as well as their magnitude and duration, determines the biological outcome of signaling, and in turn, is regulated by the identity of the ligand and the receptor composition. Recent insights into the structural basis for receptor dimerization, as provided by crystallographic analysis, are described, as is the differential activation of signaling pathways and downregulatory mechanisms. Further, dysregulation of the ErbB network is implicated in a variety of human cancers, and the nature of aberrant signaling through ErbB proteins, as well as current therapeutic approaches, are discussed, highlighting the role of the highly oncogenic ErbB-2 molecule.

[1]  O. Segatto,et al.  Negative regulation of receptor tyrosine kinase signals , 2001, FEBS letters.

[2]  M. Lisanti,et al.  Interaction of a Receptor Tyrosine Kinase, EGF-R, with Caveolins , 1997, The Journal of Biological Chemistry.

[3]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[4]  Richard J. Lee,et al.  Reciprocal Regulation of Neu Tyrosine Kinase Activity and Caveolin-1 Protein Expression in Vitro and in Vivo , 1998, The Journal of Biological Chemistry.

[5]  M. Lisanti,et al.  Caveolins in cholesterol trafficking and signal transduction: implications for human disease. , 2000, Frontiers in bioscience : a journal and virtual library.

[6]  Yosef Yarden,et al.  Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis , 1997, Neuron.

[7]  A. Thomason,et al.  Transformation of NIH 3T3 Cells by HER3 or HER4 Receptors Requires the Presence of HER1 or HER2 (*) , 1996, The Journal of Biological Chemistry.

[8]  B. Hemmings,et al.  Regulation of protein kinase B. , 1999, Journal of receptor and signal transduction research.

[9]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[10]  M. Sliwkowski,et al.  Binding specificities and affinities of egf domains for ErbB receptors , 1999, FEBS letters.

[11]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Richard G. W. Anderson,et al.  Localization of Epidermal Growth Factor-stimulated Ras/Raf-1 Interaction to Caveolae Membrane (*) , 1996, The Journal of Biological Chemistry.

[13]  M. Denton,et al.  Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor , 2001, Oncogene.

[14]  H. Esumi,et al.  Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. , 2002, Molecular biology of the cell.

[15]  Rüdiger Klein,et al.  Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor , 1995, Nature.

[16]  T. Hunter,et al.  The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. , 1999, Science.

[17]  M. Lemmon,et al.  The Single Transmembrane Domains of ErbB Receptors Self-associate in Cell Membranes* , 2002, The Journal of Biological Chemistry.

[18]  S. Courtneidge,et al.  Src family tyrosine kinases and growth factor signaling. , 2000, Experimental cell research.

[19]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[20]  Yosef Yarden,et al.  A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors , 1997, Oncogene.

[21]  O. Feron,et al.  Neuregulin signaling in the heart. Dynamic targeting of erbB4 to caveolar microdomains in cardiac myocytes. , 1999, Circulation research.

[22]  D. Johnston,et al.  Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  H. Wiley,et al.  ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor Receptors* , 1999, The Journal of Biological Chemistry.

[24]  Y. Yarden,et al.  c-Cbl Is a Suppressor of the Neu Oncogene* , 2000, The Journal of Biological Chemistry.

[25]  A. Burgess,et al.  Structure-Function relationships for the EGF/TGF-α family of mitogens , 1994 .

[26]  M. Komada,et al.  Hrs and hbp: possible regulators of endocytosis and exocytosis. , 2001, Biochemical and biophysical research communications.

[27]  J. Pierce,et al.  Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene , 1990, Molecular and cellular biology.

[28]  B. Shilo,et al.  Sprouty is a general inhibitor of receptor tyrosine kinase signaling. , 1999, Development.

[29]  S. Parsons,et al.  c-Src, receptor tyrosine kinases, and human cancer. , 1999, Advances in cancer research.

[30]  A. Lenferink,et al.  Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers , 1998, The EMBO journal.

[31]  A. Berezov,et al.  HER2/Neu: mechanisms of dimerization/oligomerization , 2002, Oncogene.

[32]  G. Carpenter Employment of the Epidermal Growth Factor Receptor in Growth Factor–Independent Signaling Pathways , 1999, The Journal of cell biology.

[33]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[34]  N. Maihle,et al.  The EGF/ErbB Receptor Family and Apoptosis , 2002, Growth factors.

[35]  R. G. Anderson The caveolae membrane system. , 1998, Annual review of biochemistry.

[36]  Paul W. Sternberg,et al.  The let-23 gene necessary for Caenorhabditis elegans vulval induction encodes a tyrosine kinase of the EGF receptor subfamily , 1990, Nature.

[37]  Yosef Yarden,et al.  Molecular mechanisms underlying ErbB2/HER2 action in breast cancer , 2000, Oncogene.

[38]  Yong Liao,et al.  HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation , 2001, Nature Cell Biology.

[39]  L. Theill,et al.  Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  L. Cantley,et al.  Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D A Lauffenburger,et al.  Intracellular Trafficking of Epidermal Growth Factor Family Ligands Is Directly Influenced by the pH Sensitivity of the Receptor/Ligand Interaction (*) , 1995, The Journal of Biological Chemistry.

[42]  D. W. Fry,et al.  Anticancer therapy targeting the erbB family of receptor tyrosine kinases. , 2001, Seminars in oncology.

[43]  Y. Yarden,et al.  ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.

[44]  M. Freeman,et al.  Inhibition of Drosophila EGF receptor activation by the secreted protein Argos , 1995, Nature.

[45]  Hyun-soo Cho,et al.  Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether , 2002, Science.

[46]  Carmen Birchmeier,et al.  Multiple essential functions of neuregulin in development , 1995, Nature.

[47]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[48]  M. Hung,et al.  Overexpression of ErbB2 in cancer and ErbB2-targeting strategies , 2000, Oncogene.

[49]  R H Perry,et al.  Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. , 1997, Cancer research.

[50]  Boon Chuan Low,et al.  Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling , 2002, The EMBO journal.

[51]  J. Brugge,et al.  Controlled Dimerization of ErbB Receptors Provides Evidence for Differential Signaling by Homo- and Heterodimers , 1999, Molecular and Cellular Biology.

[52]  M. Freeman,et al.  Complexity of EGF receptor signalling revealed in Drosophila. , 1998, Current opinion in genetics & development.

[53]  M. Lemmon,et al.  Extracellular domains drive homo‐ but not hetero‐dimerization of erbB receptors , 2000, The EMBO journal.

[54]  G. Sala,et al.  Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control , 2002, Oncogene.

[55]  Richard G. W. Anderson,et al.  Regulated Migration of Epidermal Growth Factor Receptor from Caveolae* , 1999, The Journal of Biological Chemistry.

[56]  Jun Yao,et al.  Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. , 1998, Molecular cell.

[57]  John M. Daly,et al.  ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency , 2000, Molecular and Cellular Biology.

[58]  P. Sternberg,et al.  ARK-1 inhibits EGFR signaling in C. elegans. , 2000, Molecular cell.

[59]  D. Bigner,et al.  Molecular pathogenesis of malignant gliomas. , 1999, Current opinion in oncology.

[60]  K. Carraway,et al.  Neuregulins and their receptors , 1995, Current Opinion in Neurobiology.

[61]  M. Hung,et al.  Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.

[62]  L. Cantley,et al.  p120 Is a Cytosolic Adapter Protein That Associates with Phosphoinositide 3-Kinase in Response to Epidermal Growth Factor in PC12 and Other Cells (*) , 1996, The Journal of Biological Chemistry.

[63]  Y. Yarden,et al.  Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network , 1998, The EMBO journal.

[64]  Y. Yarden,et al.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[65]  H. Modjtahedi,et al.  Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. , 2000, Cancer research.

[66]  S. Hubbard,et al.  Autoregulatory Mechanisms in Protein-tyrosine Kinases* , 1998, The Journal of Biological Chemistry.

[67]  L. Cantley,et al.  Ligand Discrimination in Signaling through an ErbB4 Receptor Homodimer* , 2000, The Journal of Biological Chemistry.

[68]  N. Perrimon,et al.  The Transmembrane Molecule Kekkon 1 Acts in a Feedback Loop to Negatively Regulate the Activity of the Drosophila EGF Receptor during Oogenesis , 1999, Cell.

[69]  W. Cavenee,et al.  Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[71]  Yosef Yarden,et al.  Biology of HER2 and Its Importance in Breast Cancer , 2001, Oncology.

[72]  Kuo-Fen Lee,et al.  Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.

[73]  H. Lee,et al.  EGF/ErbB receptor family in ovarian cancer. , 2002, Cancer treatment and research.

[74]  A. Ullrich,et al.  The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. , 2001, Endocrine-related cancer.

[75]  M. Sliwkowski,et al.  A Discrete Three-amino Acid Segment (LVI) at the C-terminal End of Kinase-impaired ErbB3 Is Required for Transactivation of ErbB2* , 1999, The Journal of Biological Chemistry.

[76]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, The oncologist.

[77]  Cori Bargmann,et al.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.

[78]  A. Wells,et al.  Signalling shortcuts: cell-surface receptors in the nucleus? , 2002, Nature Reviews Molecular Cell Biology.

[79]  Monilola A. Olayioye,et al.  The ErbB receptor tyrosine family as signal integrators. , 2001, Endocrine-related cancer.

[80]  G. Carpenter,et al.  The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. , 1993, Oncogene.

[81]  S. Aaronson,et al.  The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. , 1990, The New biologist.

[82]  S. Aaronson,et al.  Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene , 1988, Molecular and cellular biology.

[83]  A Ciechanover,et al.  Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. , 1999, Molecular cell.

[84]  Y. Yarden,et al.  Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. , 1996, Oncogene.

[85]  Jae-Hoon Kim,et al.  Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.

[86]  M. Kraus,et al.  Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.

[87]  R. Kumar,et al.  The role of HER2 in angiogenesis. , 2001, Seminars in oncology.

[88]  Y. Yarden,et al.  Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. , 2000, Cancer research.

[89]  R. Weinberg,et al.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.

[90]  M. Roussel,et al.  Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.

[91]  Monilola A. Olayioye,et al.  ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner , 1998, Molecular and Cellular Biology.

[92]  Edouard C. Nice,et al.  Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.

[93]  J. Engelman,et al.  Targeted downregulation of caveolin‐1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade , 1998, The EMBO journal.

[94]  I. Lorimer Mutant epidermal growth factor receptors as targets for cancer therapy. , 2002, Current cancer drug targets.

[95]  L. Neckers,et al.  Hsp90 inhibitors as novel cancer chemotherapeutic agents. , 2002, Trends in molecular medicine.

[96]  J. Biegel,et al.  Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. , 1995, Cancer research.

[97]  M. Sliwkowski,et al.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.

[98]  A. Ullrich,et al.  Smart drugs: tyrosine kinase inhibitors in cancer therapy. , 2002, Cancer cell.

[99]  J. Massagué,et al.  Membrane-anchored growth factors. , 1993, Annual review of biochemistry.

[100]  Y. Yarden,et al.  Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway , 2000, Molecular and Cellular Biology.

[101]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[102]  B. Geiger,et al.  Alternative Intracellular Routing of ErbB Receptors May Determine Signaling Potency* , 1998, The Journal of Biological Chemistry.

[103]  R. Neve,et al.  Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells , 2000, Oncogene.

[104]  Y. Yarden,et al.  A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.

[105]  R. Ward,et al.  Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines , 2001, Cancer Immunology, Immunotherapy.

[106]  H. P. Fell,et al.  The Relationship between Human Epidermal Growth-like Factor Receptor Expression and Cellular Transformation in NIH3T3 Cells* , 1996, The Journal of Biological Chemistry.

[107]  Y. Yarden,et al.  Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. , 2000, Advances in cancer research.

[108]  A. Ullrich,et al.  Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission , 2001, Oncogene.

[109]  C. Heldin,et al.  Dimerization of cell surface receptors in signal transduction , 1995, Cell.

[110]  N. Goldstein,et al.  Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.

[111]  N. Normanno,et al.  Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs): Simple drugs with a complex mechanism of action? , 2003, Journal of cellular physiology.

[112]  T. Pawson,et al.  SH2 domains recognize specific phosphopeptide sequences , 1993, Cell.

[113]  M. Lisanti,et al.  Caveolin-1, a putative tumour suppressor gene. , 2001, Biochemical Society transactions.

[114]  H. Poulsen,et al.  The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[115]  G. Hortobagyi,et al.  Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol , 1998, Oncogene.

[116]  D. Bigner,et al.  EGFRvIII as a promising target for antibody-based brain tumor therapy , 2006, Brain Tumor Pathology.

[117]  K. Makino,et al.  HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. , 2000, Cancer research.

[118]  M. Crescenzi,et al.  Inhibition of ErbB-2 Mitogenic and Transforming Activity by RALT, a Mitogen-Induced Signal Transducer Which Binds to the ErbB-2 Kinase Domain , 2000, Molecular and Cellular Biology.

[119]  M. Sliwkowski,et al.  Perspectives on Anti-HER Monoclonal Antibodies , 2002, Oncology.

[120]  Lucas Pelkmans,et al.  Endocytosis Via Caveolae , 2002, Traffic.

[121]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[122]  M. Sliwkowski,et al.  A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. , 2001, Cancer research.

[123]  A. Berezov,et al.  HER2/Neu: mechanisms of dimerization/oligomerization , 2000, Oncogene.

[124]  G. Carpenter,et al.  All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*) , 1996, The Journal of Biological Chemistry.

[125]  T. van Raaij,et al.  The cellular response to neuregulins is governed by complex interactions of the erbB receptor family , 1995, Molecular and cellular biology.

[126]  N. Rosen,et al.  Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. , 2002, Cancer research.

[127]  Y. Yarden,et al.  Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases , 2001, FEBS letters.

[128]  S. Sharpe,et al.  Interaction between ErbB‐1 and ErbB‐2 transmembrane domains in bilayer membranes , 2002, FEBS letters.

[129]  R. Cardiff,et al.  Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.

[130]  Y. Yarden,et al.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.

[131]  Richard G. W. Anderson,et al.  Cholesterol Depletion of Caveolae Causes Hyperactivation of Extracellular Signal-related Kinase (ERK)* , 1998, The Journal of Biological Chemistry.